HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma

Cecilia Midulla, Lucia Manganaro, Flavia Longo, Valentina Viggiani, Luigi Frati, Teresa Granato, Emanuela Anastasi

Research output: Contribution to journalArticlepeer-review

Abstract

The purpose of the study was to evaluate the expression of the biomarkers CA125 and HE4 combined with imaging, in patients with advanced epithelial ovarian cancer (EOC). Forty-six women with EOC were included in the study all affected with peritoneal carcinomatosis. Twenty-two of 46 patients (group I) had peritoneal carcinomatosis with small implants in single or in multiple sites (score 1); 24/46 patients (group II) had macro-nodular implants and omental thickening (score 2). High levels of CA125 (350 ± 11, mean ± SEM) have been observed in 21/22 patients of group I, and a similar value (370 ± 13) has been observed in all patients belonging to group II. HE4 positivity values (350 ± 9) have been observed in all group I patients, whereas all patients belonging to group II showed a higher value of HE4 (600 ± 12). Statistically significant differences were observed between the HE4 levels observed in group I patients in comparison with group II patients (p <0.0001). In addition, we expressed the extension of lymph nodal disease in three scores: L1-L2-L3, and a statistically significant correlation was observed between high HE4 levels and severity of lymph nodal disease L3 (p <0.0001). The availability of biomarkers, particularly HE4, together with sophisticated imaging techniques, strengthens the clinical relevance of this study, for the follow-up of patients with peritoneal carcinomatosis.

Original languageEnglish
Pages (from-to)1291-1298
Number of pages8
JournalTumor Biology
Volume33
Issue number5
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Biomarkers
  • CA125
  • Carcinomatosis
  • HE4
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma'. Together they form a unique fingerprint.

Cite this